Viewing Study NCT06291857



Ignite Creation Date: 2024-05-06 @ 8:13 PM
Last Modification Date: 2024-10-26 @ 3:22 PM
Study NCT ID: NCT06291857
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-05-13
First Post: 2024-03-01

Brief Title: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Sponsor: Novavax
Organization: Novavax

Study Overview

Official Title: A Randomized Observer-Blinded Active-Controlled Study to Evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants 65 Years of Age
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this Phase 3 study is to compare the effectiveness safety and side effects of the CIC vaccine with approved flu vaccines and the Novavax COVID-19 Vaccine with adjuvant
Detailed Description: This is a large study to test how well a new combination vaccine for COVID-19 and influenza the CIC vaccine works in adults 65 and older compared to other vaccines The study will check if the CIC vaccine triggers a similar or better immune response measured by antibody levels than the Fluzone High-Dose influenza vaccine and the Novavax COVID-19 vaccine It will also test a new standalone flu vaccine tNIV to see if it works as well as Fluzone High-Dose

The study has two parts

Part 1 will include up to 4950 adults and will test how well both CIC and tNIV vaccines trigger an immune response and track side effects

Part 2 will include up to 3000 adults to further monitor the safety of both vaccines

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None